SW Investments is a holding company that generates income by investing in equity shares, debentures, and alternative investment funds, while also providing financial consultancy and brokerage services.
The company lacks a competitive advantage, as evidenced by an average ROCE of 4.3% which is likely below its cost of capital. Its primary activity is passive investment in other entities, offering no unique product or cost advantage that would protect it from competitors.
Management primarily retains earnings to reinvest in financial instruments and alternative investment funds. While the company maintains zero debt, the returns on these investments are low, and there is no track record of returning capital to shareholders via dividends despite high cash conversion.
The company's capital was slowly eroded as the concentrated investment in a single Alternative Investment Fund soured, while the massive related-party loans to Starteck Finance Limited became unrecoverable during a credit tightening. With only one permanent employee to oversee a complex portfolio of financial instruments, the lack of institutional oversight led to poor risk management. The market eventually realized that the company was merely a stagnant pool of low-yield assets with no operational engine, causing the share price to collapse toward the underlying book value of its mediocre investments.
RichFakir rates SW Investments Ltd's business quality as poor — 33/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, SW Investments Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on SW Investments Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of SW Investments Ltd's fair value is about ₹15 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →